Table 2.
Initial medication after HTX
| Parameter | FEV1/FVC <0.70 (n=63) | FEV1/FVC ≥0.70 (n=196) | Difference (%) | 95% CI |
|---|---|---|---|---|
| Cyclosporine A, n (%) | 12 (19.0%) | 57 (29.1%) | 10.1 | −1.6%, 21.8% |
| Tacrolimus, n (%) | 51 (81.0%) | 139 (70.9%) | 10.1 | −1.6%, 21.8% |
| Azathioprine, n (%) | 0 (0.0%) | 1 (0.5%) | 0.5 | −0.5%, 1.5% |
| Mycophenolate mofetil, n (%) | 63 (100.0%) | 195 (99.5%) | 0.5 | −0.5%, 1.5% |
| Steroids, n (%) | 63 (100.0%) | 196 (100.0%) | 0.0 | NA |
| Acetylsalicylic acid, n (%) | 11 (17.5%) | 18 (9.2%) | 8.3 | −1.9%, 18.5% |
| β-blocker, n (%) | 14 (22.2%) | 44 (22.4%) | 0.2 | −11.6%, 12.0% |
| Ivabradine, n (%) | 5 (7.9%) | 25 (12.8%) | 4.9 | −3.3%, 13.1% |
| Calcium channel blocker | 14 (22.2%) | 53 (27.0%) | 4.8 | −7.2%, 16.8% |
| Dihydropyridine, n (%) | 5 (7.9%) | 26 (13.2%) | 5.3 | −2.9%, 13.5% |
| Nondihydropyridine, n (%) | 9 (14.3%) | 27 (13.8%) | 0.5 | −9.4%, 10.4% |
| ACE inhibitor, n (%) | 16 (25.4%) | 73 (37.2%) | 11.8 | −0.9%, 24.5% |
| Diuretic, n (%) | 63 (100.0%) | 196 (100.0%) | 0.0 | NA |
| Statin, n (%) | 36 (57.1%) | 130 (66.3%) | 9.2 | −4.7%, 23.1% |
| Gastric protection (PPI/H2 blocker), n (%) | 63 (100.0%) | 196 (100.0%) | 0.0 | NA |
Abbreviations: ACE inhibitor, angiotensin-converting enzyme inhibitor; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FEV1/FCV, Tiffeneau index; H2 blocker, histamine receptor blocker; HTX, heart transplantation; NA, not applicable; PPI, proton pump inhibitor;.